Cargando…

Weekly versus biweekly bortezomib given in patients with indolent non-Hodgkin lymphoma: A meta-analysis

BACKGROUND: Bortezomib is recently studied as a novel agent in indolent lymphoma. The optimal schedule of bortezomib used in indolent lymphoma is still uncertain. METHODS: We did a systematic review and meta-analysis of the clinical trials comparing the efficacy and toxicity of the weekly and biweek...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yuan, Ting, Zhang, Feng, Yao, Qing-min, Liu, Yan-xia, Zhu, Xiao-juan, Wang, Xin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439710/ https://www.ncbi.nlm.nih.gov/pubmed/28531181 http://dx.doi.org/10.1371/journal.pone.0177950

Ejemplares similares

Immunotherapy in indolent Non-Hodgkin's Lymphoma
por: Amhaz, Ghid, et al.
Publicado: (2022)

Pharmacokinetic Analysis of Weekly Versus Biweekly IgPro20 Dosing in Patients With Primary Immunodeficiency
por: Rojavin, Mikhail A., et al.
Publicado: (2019)

Real-world comparison between weekly versus biweekly dosing of cetuximab for metastatic colorectal cancer
por: Aggarwal, Himani, et al.
Publicado: (2023)

The role of bendamustine in the treatment of indolent non-Hodgkin lymphoma
por: Aldoss, Ibrahim T, et al.
Publicado: (2009)

Update on treatment of follicular non-Hodgkin’s lymphoma: focus on potential of bortezomib
por: Brander, Danielle M, et al.
Publicado: (2012)

Novel Therapies for Follicular Lymphoma and Other Indolent Non-Hodgkin Lymphomas
por: Leslie, Lori A.
Publicado: (2021)

Bendamustine: Safety and Efficacy in the Management of Indolent Non-Hodgkins Lymphoma
por: Tageja, Nishant
Publicado: (2011)

Bendamustine HCL for the treatment of relapsed indolent non-Hodgkin’s lymphoma
por: Weide, Rudolf
Publicado: (2008)

Role of antibody-based therapy in indolent non-Hodgkin's lymphoma
por: Willard, Patrick, et al.
Publicado: (2021)

Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphoma
por: Phillips, Tycel, et al.
Publicado: (2022)

Therapeutic Activity of Lenalidomide in Mantle Cell Lymphoma and Indolent Non-Hodgkin's Lymphomas
por: Gunnellini, Marco, et al.
Publicado: (2012)

Targeted Agents in the Treatment of Indolent B-Cell Non-Hodgkin Lymphomas
por: Minson, Adrian, et al.
Publicado: (2022)

Increased plasma endostatin and GDF15 in indolent non-Hodgkin lymphoma
por: Hidman, Josefin, et al.
Publicado: (2023)

Comparison of the effects of weekly and biweekly intravenous CERA administration on erythropoiesis: A randomized controlled trial
por: Kawai, Yuki, et al.
Publicado: (2021)

An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma
por: Andorsky, David J., et al.
Publicado: (2018)

Comparison of CT, PET, and PET/CT for Staging of Patients with Indolent Non-Hodgkin’s Lymphoma
por: Fueger, Barbara J., et al.
Publicado: (2009)

Idelalisib for the treatment of indolent non-Hodgkin lymphoma: a review of its clinical potential
por: Barrientos, Jacqueline C
Publicado: (2016)

The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas
por: Artemaki, Pinelopi I., et al.
Publicado: (2021)

Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin’s lymphoma: a monocenter analysis
por: Hadi, I., et al.
Publicado: (2021)

Factors Impacting Treatment Decision Making in Older Adults With Indolent Non-Hodgkin Lymphoma
por: Trevino, Kelly, et al.
Publicado: (2021)

Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer
por: Chon, Hong Jae, et al.
Publicado: (2011)

Clinical Trials Portfolio and Regulatory History of Idelalisib in Indolent Non-Hodgkin Lymphoma: A Systematic Review and Meta-analysis
por: Banerjee, Titas, et al.
Publicado: (2023)

Biweekly Versus Monthly Hyperimmune Globulin Therapy for Primary Cytomegalovirus Infection in Pregnancy
por: Schirwani-Hartl, Nawa, et al.
Publicado: (2023)

Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis
por: Parikh, Aparna R, et al.
Publicado: (2022)

Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial
por: Nishida, Yoshihiro, et al.
Publicado: (2020)

A prospective, randomised comparative study of weekly versus biweekly application of dehydrated human amnion/chorion membrane allograft in the management of diabetic foot ulcers
por: Zelen, Charles M, et al.
Publicado: (2014)

An evaluation of the potential for drug–drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma
por: Darwish, Mona, et al.
Publicado: (2014)

Arsenic trioxide rewires mantle cell lymphoma response to bortezomib
por: Zhao, Ling-Ling, et al.
Publicado: (2015)

RCHOP-14 therapy versus RCHOP-21 therapy for people with aggressive or advanced-stage indolent B-cell non-Hodgkins lymphoma: a systematic review and meta-analysis
por: He, Yue, et al.
Publicado: (2021)

Indole-3-carbinol synergistically sensitises ovarian cancer cells to bortezomib treatment
por: Taylor-Harding, B, et al.
Publicado: (2012)

Dendritic cell vaccine treatment for indolent B cell non-hodgkin lymphoma: clinical trial in progress
por: Lin, Yi, et al.
Publicado: (2014)

Toxic Encephalopathy After Relapsed Indolent Non-Hodgkin’s Lymphoma Following Abrupt Discontinuation of Idelalisib (ZYDELIG®)
por: Shenouda, Mina, et al.
Publicado: (2019)

Cellular function given parametric variation in the Hodgkin and Huxley model of excitability
por: Ori, Hillel, et al.
Publicado: (2018)

Posterior scleritis after biweekly aflibercept intravitreal injections
por: Hébert, Mélanie, et al.
Publicado: (2022)

Once-weekly bortezomib had similar effectiveness and lower thrombocytopenia occurrence compared with twice-weekly bortezomib regimen in treating patients with newly diagnosed multiple myeloma in China
por: Yao, Rongxin, et al.
Publicado: (2019)

Bendamustine as first-line treatment in patients with advanced indolent non-Hodgkin lymphoma and mantle cell lymphoma in German routine clinical practice
por: Becker, M., et al.
Publicado: (2015)

Treatment of indolent lymphoma
por: Jeong, Seong Hyun
Publicado: (2022)

A retrospective study of 101 dogs with oral melanoma treated with a weekly or biweekly 6 Gy × 6 radiotherapy protocol
por: Baja, Alexie J., et al.
Publicado: (2022)

Randomized Phase II Study of First‐Line Biweekly Gemcitabine and Carboplatin Versus Biweekly Gemcitabine and Carboplatin plus Maintenance Gemcitabine in Elderly Patients with Untreated Non‐Small Cell Lung Cancer: LOGIK0801
por: Takayama, Koichi, et al.
Publicado: (2020)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
por: Dolph, Michael, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ktrf8cnggpf28u60ts36a2n0mj